Pneumococcal (20-valent) vaccine is under clinical development by Suzhou Weichao Biotechnology and currently in Phase I for Streptococcal Pneumonia. According to GlobalData, Phase I drugs for Streptococcal Pneumonia have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pneumococcal (20-valent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pneumococcal (20-valent) vaccine overview

Vaccine is under development for the prevention of Streptococcal pneumonia infections, meningitis and sepsis caused by pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. It is a 20-valent conjugated vaccine. It is administered through intramuscular route.

Suzhou Weichao Biotechnology overview

Suzhou Weichao Biotechnology (Weichao Biotechnology) operate in healthcare sector. Weichao Biotechnology is headquartered in Suzhou, Jiangsu, China.

For a complete picture of Pneumococcal (20-valent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.